Oxidative Stress: An Accomplice to Uremic Toxicity?

Journal of Renal Nutrition

Volumn 16, Issue 3, 2006, Pages 194-198

  Mircescu, Gabriel ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; NUCLEIC ACID; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ARTICLE; CHRONIC KIDNEY FAILURE; HUMAN; LIPID PEROXIDATION; METABOLISM; OXIDATIVE STRESS; PERITONEAL DIALYSIS; RENAL REPLACEMENT THERAPY; UREMIA;

ANTIOXIDANTS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDATION; NUCLEIC ACIDS; OXIDATIVE STRESS; PERITONEAL DIALYSIS; RENAL DIALYSIS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; UREMIA;

EID: 33745668880     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2006.04.015     Document Type: Article

References (16)

1. Miyata T., van Ypersele de Strihou C.H., Kurokawa K., et al. Alterations in nonenzymatic biochemistry in uremia. Origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55 (1999) 389-399
2. Witko-Sarsat V., Friedlander M., Capeillere-Blandin C., et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49 (1996) 1304-1313
3. Fragedaki E., Nebel M., Schupp N., et al. Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis. Nephrol Dial Transplant 20 (2005) 1936-1943
4. Cǎpuşǎ C., Mircescu G., Stoian I., et al. Intradialytic variations of oxidative stress markers. Nefrologia 9 (2004) 69-78
5. Mircescu G., Cǎpuşǎ C., Stoian I., et al. Oxidative and carbonyl stress in chronic renal failure patients. There is a relationship?. Nefrologia 9 (2004) 165-172
6. Mircescu G., Cǎpuşǎ C., Stoian I., et al. Influence of epoietinum therapy on the oxidative stress in haemodialysis patients. Nephron Clin Pract 100 (2005) 126-132
7. Ursea N., Mircescu G., Cǎpuşǎ C., et al. Hemodialysis. Main or additional factor for the oxidative stress in chronic renal failure patients?. Proceedings of the Romanian Academy, Series B 3 (2001) 241-246
8. NKF K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 45 Suppl 3 (2005) S1-S135
9. Boaz M., Matas Z., Biro A., et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 56 (1999) 1078-1083
10. Stenvinkel P., Diczfalusy U., Lindholm B., et al. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol Dial Transplant 19 (2004) 972-976
11. Descamps-Latscha B., Witko-Sarsat V., Nguyen-Khoa T., et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 45 (2005) 39-47
12. Busch M., Franke S., Müller A., et al. Potential cardiovascular risk factors in chronic kidney disease. AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 66 (2004) 338-347
13. Schwedler S.B., Metzger T., Schinzel R., et al. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 62 (2002) 301-310
14. Schwedler S.B., Schinzel R., Vaith P., et al. Inflammation and advanced glycation end products in uremia. Simple coexistence, potentiation or causal relationship?. Kidney Int 59 suppl 78 (2001) S32-S36
15. Bayés B., Cruz-Pastor M., Bonal J., et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 18 (2003) 106-112
16. Tsimikas S., Emmanouil D., Brilakis S., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353 (2005) 46-57